| Lumos Pharma–UCB: investment, 201604 financing round Series B totalling $34m incl existing + co-investor UCB |
2016-04-06 |
| Thermosome–Bavaria (govt): investment, 201604 1st financing round totalling €1.9m incl HTGF + Bayern Kapital + private investors |
2016-04-06 |
| Thermosome–Germany (govt): grant, 201604– BMBF grant €2.7m 3y as part of TSL-LIFU project consortium |
2016-04-06 |
| Thermosome–High-Tech Gründerfonds: investment, 201604 1st financing round totalling €1.9m incl HTGF + Bayern Kapital + private investors |
2016-04-06 |
| Thermosome–SEVERAL: investment, 201604 1st financing round €1.9m from HTGF + Bayern Kapital + private investors |
2016-04-06 |
| Qiagen–BioTeam: bioinformatics, 201604 collab existent to create high-performance appliance with CLC Genomics Server + BioTeam Appliance platform |
2016-04-05 |
| Qiagen–Intel: bioinformatics, 201604 collab existent to develop reference architecture for high-volume whole genome data analysis |
2016-04-05 |
| Anergis–SEVERAL: investment, 201604 financing round extension CHF5m to conduct phase 2b study with AllerT from existing investors |
2016-04-04 |
| Immunocore–Medigene: investment, 201604 DIVESTMENT sale of 50% of Medigene’s stake in Immunocore for £4.9m (€6.1m) |
2016-04-04 |
| Metabomed–Boehringer: investment, 201604 financing round Series A totalling $18m incl investors MS Ventures + BIVF et al |
2016-04-04 |
| Metabomed–Merck (DE): investment, 201604 financing round Series A totalling $18m incl investors MS Ventures + BIVF et al |
2016-04-04 |
| Metabomed–SEVERAL: investment, 201604 financing round Series A extension bringing total Series A round to close with $18m |
2016-04-04 |
| Fusion Antibodies–MAB Discovery: antibody technology, 201603– collab + license use CDRx humanisation w rabbit-based MAb technology for therap MAbs |
2016-03-31 |
| NEO New Oncology–Siemens: investment, 201603 acquisiton by Siemens Healthcare GmbH |
2016-03-31 |
| Amal Therapeutics–Boehringer: investment, 201603 financing round Series A totalling CHF3m incl lead investor BIVF |
2016-03-30 |
| Amal Therapeutics–High-Tech Gründerfonds: investment, 201603 financing round Series A totalling CHF3m incl co-investor HTGF |
2016-03-30 |
| Amal Therapeutics–Instinctif Partners: public relations, 201603 service existent by Instinctif Partners |
2016-03-30 |
| Amal Therapeutics–SEVERAL: investment, 201603 financing round Series A CHF3m led by BIVF with co-investors VI Partners + HTGF |
2016-03-30 |
| Amal Therapeutics–VI Partners: investment, 201603 financing round Series A totalling CHF3m incl co-investor VI Partners |
2016-03-30 |
| BioChain–Epigenomics: molecular diagnostics, 201603– license excl blood-based lung cancer test for developm + commercialisation in China |
2016-03-30 |
| Zavante Therapeutics–SEVERAL: investment, 201603 financing round Series A $45m with $35m from new investors + $10m conversion of convertible notes |
2016-03-30 |
| Exiqon–Qiagen: investment, 201603–201606 conditional voluntary takeover offer DKK683m ($100m) |
2016-03-29 |
| Gadeta–SEVERAL: investment, 201603 financing round Series A €7m led by Medicxi Ventures + Baxalta Ventures with Utrecht Holdings + founders + managers |
2016-03-29 |
| ABBA Therapeutics–Ligand: transgenic animal technology, 201603– license to use OmniAb platform to develop MAbs + bi-specific ABs |
2016-03-28 |
| Bayer–Holta Invest: investment, 201603 existent Bayer listed as portfolio company of Holta Life Sciences |
2016-03-28 |
| Roche–Holta Invest: investment, 201603 existent Roche listed as portfolio company of Holta Life Sciences |
2016-03-28 |
| Diatron–Stratec: investment, 201603 acquisition 100% of Diatron MI PLC by Stratec from The Riverside Company |
2016-03-23 |
| Padlock Therapeutics–BMS: investment, 201603–201604 acquisition 100% for up to $600m |
2016-03-23 |
| Thuringia (govt)–High-Tech Gründerfonds: venture capital, 201603– collab renewed TSF + HTGF to jointly provide up to €3.15m for early financings |
2016-03-23 |
| Topas Therapeutics–EMBL: investment, 201603 financing round Series A totalling €14m incl co-investor EMBL Ventures |
2016-03-22 |
| Topas Therapeutics–Epidarex Capital: investment, 201603 financing round Series A totalling €14m led by Epidarex |
2016-03-22 |
| Topas Therapeutics–Evotec: investment, 201603 financing round Series A totalling €14m incl co-investor Evotec AG |
2016-03-22 |
| Topas Therapeutics–Gimv: investment, 201603 financing round Series A totalling €14m incl €4m from co-investor Gimv Health & Care |
2016-03-22 |
| Topas Therapeutics–SEVERAL: investment, 201603 financing round Series A €14m led by Epidarex incl EMBL Ventures + Gimv + Evotec |
2016-03-22 |
| GSK–Miltenyi Biotec: cell/gene therapy, 201603– collab cell + gene therapy incl CAR-T using increased automation |
2016-03-16 |
| SkyePharma–Vectura: investment, 201603– acquisition merger £441m in shares (up to £70m cash) resulting in 41.75% (37.62%) for former Skye owners |
2016-03-16 |
| Almirall–Grünenthal: investment, 201603– acquisition 100% of Almirall de Mexico SA de CV by Grünenthal ANNNOUNCED |
2016-03-15 |
| Bohui–Univ Freiburg: mass spec sample introduction technique, –201603 collab developm iASAP Prof Krossing + license of patent rights to Advion |
2016-03-15 |
| Roche–Blueprint Medicines: kinase inhibitors, 201603– collab ww $45m upfront + $965m milestones r+d + commerc up to 5 small molelcule drugs |
2016-03-15 |
| eTheRNA–Boehringer: investment, 201603 financing round Series A totalling €24m incl co-investor BIVF |
2016-03-14 |
| eTheRNA–Flanders (govt): investment, 201603 financing round Series A totalling €24m led by PMV + Life Sciences Partners |
2016-03-14 |
| eTheRNA–Fund+: investment, 201603 financing round Series A totalling €24m incl co-investor Fund+ |
2016-03-14 |
| eTheRNA–Life Sciences Partners: investment, 201603 financing round Series A totalling €24m led by Life Sciences Partners + PMV |
2016-03-14 |
| eTheRNA–Omega Advisors: investment, 201603 financing round Series A totalling €24m incl co-investor Omega Funds |
2016-03-14 |
| eTheRNA–SEVERAL: investment, 201603 financing round Series A €24m led by Life Sciences Partners + PMV |
2016-03-14 |
| Agilent–Eurofins: genomic technology, 201603– collab Eurofins Genomics supplies custom components for Agilent’s SureVector cloning kits |
2016-03-10 |
| Aprea–MC Services: public relations, 201602 service existent for Aprea AB |
2016-03-09 |
| AbbVie–Boehringer: therap antibodies, 201603– collab + acqu ww rights BI 655066 + BI 655064 for $595m upfront + undisclosed milestones + royalties |
2016-03-07 |
| Argos–SEVERAL: investment, 201603– securities purchase agreem up to $60m common stock + warrants in 3 tranches incl Pharmstandard + TVM |
2016-03-07 |
| ITM Isotopen Technologien München–OTHER: investment, 201603 equity investment €20m from Medtech-focused family office |
2016-03-07 |
| Biocom–Nasdaq OMX: press release distribution, 201603 collab existent integration of channel news in Eurobiotechnews.eu portal |
2016-03-06 |
| Snowy Range Instruments–Metrohm: investment, 201603 acquisition of majority by Metrohm + SnRI renamed Metrohm Raman |
2016-03-04 |
| Biolink (NO)–Evonik: investment, 201603 acquisition €na of MedPalett AS by Evonik from Biolink Group |
2016-03-03 |
| Grünenthal–Axxam: drug discovery services, 201603– collab to discover small moleucule lead structures to treat pain + inflammation |
2016-03-03 |
| Pulsar Photonics–High-Tech Gründerfonds: investment, 201603 seed financing from HTGF |
2016-03-02 |
| Cycle GmbH–Hamburg (govt): investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–High-Tech Gründerfonds: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–PERSON: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–SEVERAL: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Merck (DE)–EMBL: drug discovery, 201603–201902 collab research 3y with EMBL Heidelberg w focus on cancer metabolism |
2016-03-01 |
| Retina Implant–SEVERAL: investment, 201602 private equity funding round €26m from existing + new investors |
2016-02-29 |
| CPGR (ZA)–Thermo Fisher: mass spectrometer, 201602 supply existent Q Exactive MS system used for proteomics |
2016-02-26 |
| Blue Scientific–Accurion: laboratory instruments, 201602– distribution Nanofilm Technology + Halcyonics products in UK + Nordics by Blue Scientific |
2016-02-25 |
| Pronutria–Nestlé: investment, 201602 equity investment $42.5m by Nestlé Health Science |
2016-02-23 |
| Ergomed–MC Services: public relations, 201602 service existent for Ergomed plc |
2016-02-18 |
| MorphoSys–MC Services: public relations, 201602 service existent for MorphoSys AG |
2016-02-18 |
| Newron–MC Services: public relations, 201602 service existent for Newron Pharmaceuticals |
2016-02-18 |
| Strüngmann Group–MC Services: public relations, 201602 service existent for AiCuris Anti-infective Cures GmbH |
2016-02-18 |
| Transcend Medical–Novartis: investment, 201602 acquisition €na by Alcon |
2016-02-18 |
| Ipsen–3B Pharmaceuticals: radiopharmaceutical, 201602– license ww excl for radiopharmaceuticals in oncology |
2016-02-17 |
| Saphetor–Capricorn One: public relations, 201602 service existent for Saphetor SA |
2016-02-17 |
| Saphetor–SEVERAL: investment, 201602 seed financing round CHF1.2m from undisclosed investors |
2016-02-17 |
| Venture Valuation–Nasdaq OMX: press release distribution, 201602– collab integration of channel news in Biotechgate online directories |
2016-02-17 |
| Apogenix–Germany (govt): grant, 201602 BMBF grant €3m for developm of companion diagnostic w R-Biopharm for APG101 in glioblastoma |
2016-02-16 |
| Merck (DE)–Weizmann Institute: life sciences, 201602– collab 3y framework agreement research |
2016-02-16 |
| Novartis–Pfizer: biosimilar, 201602– Sandoz acquires rights to PF-06438179 (infliximab) in EEA which Pfizer had to divest after Hospira acquisition |
2016-02-12 |
| Curetis–Degroof Petercam: financial services, 201602– supply service liquidity provider to facilitate share trading on Euronext Brussels + Amsterdam |
2016-02-11 |
| Armo BioSciences–HBM: investment, 201602 private financing round Series C totalling $50m incl $10m from new investor HBM Healthcare Investments |
2016-02-10 |
| Armo BioSciences–SEVERAL: investment, 201602 private financing round Series C $50m from existent + new investors |
2016-02-10 |
| Hemovent–SEVERAL: investment, 201602 financing round Series A $6m led by MIG Verwaltungs AG |
2016-02-10 |
| Qiagen–10x Genomics: genomic technology, 201602– collab co-developm + co-marketing of NGS + single-cell biology + bioinformatics solutions |
2016-02-09 |
| Sophia Genetics–Swift Biosciences: molecular diagnostics, 201602– collab product integration offering combined MDx solutions in Europe |
2016-02-09 |
| Tollys–Riboxx: cancer drug, 201602– license ww excl to Apoxxim TLR3-ligand programme to Tollys |
2016-02-04 |
| Univ Rochester–Indivumed: tissue bank, 201602– collab 3y €na to establish UMRC-Indivumed tissue bank for cancer research |
2016-02-04 |
| Labiotech.eu–SEVERAL: investment, 201602 seed financing round €6-digit led by WestTech Ventures |
2016-02-03 |
| SmartDyeLivery–SEVERAL: investment, 201602 seed financing from bm|t + Sparkasse Jena-Saale-Holzland |
2016-02-03 |
| Syngenta–ChemChina: investment, 201602– recommended cash acquisition offer valuing Syngenta at over $43b ANNOUNCED |
2016-02-03 |
| Evotec–Michael J Fox Foundation: grant, 201602 research grant for further developm of TargetaSN programme to treat Parkinson’s disease |
2016-02-02 |
| Medicxi Ventures–SEVERAL: investment, 201602 closing €210m of MV1 fund incl investments from GSK + JnJ Innovation JJDC |
2016-02-02 |
| Mission Therapeutics–Roche: investment, 201602 financing round totalling £60m incl returning co-investor Roche Venture Fund |
2016-02-02 |
| Mission Therapeutics–SEVERAL: investment, 201602 financing round £60m led by Imperial Innovations + new investor Woodford PCT |
2016-02-02 |
| Qiagen–CosmosID: bioinformatics, 201602– collab integration of CosmosID metagenomics analysis platform in CLC Genomics Workbench |
2016-02-02 |
| Alere–Abbott: investment, 201602– acquisition $5.8b equity value with $56/share ANNOUNCED |
2016-02-01 |
| InflaRx–MC Services: public relations, 201601 service existent by MC Services AG |
2016-01-28 |
| Medigene–Univ Lausanne: TCR technology, 201601– collab €na service by UNIL using NTAmer technology of TCMetrix |
2016-01-25 |
| Merck (US)–Affimed: cancer immunotherapy, 201601– collab €na clinical research combining AFM13 w pembrolizumab in Hodgkin lymphoma |
2016-01-25 |
| SeNostic–SEVERAL: investment, 201601 seed financing round led by HTGF |
2016-01-25 |
| RA-MAP Consortium–Protagen: biomarker discovery, 201601– collab Protagen joins RA-MAP Consortium contributing SeroTag platform for RA biomarker search |
2016-01-21 |
| Synoste–Evonik: investment, 201601 financing round Series A single-digit €n from Evonik + HTGF + Finnvera + Lifeline Ventures + business angels |
2016-01-21 |
| Synoste–High-Tech Gründerfonds: investment, 201601 financing round Series A single-digit €m from Evonik + HTGF + Finnvera + Lifeline Ventures + angels |
2016-01-21 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
1 2 3 ... 21 22 23 ... 53 54 55 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
